Buprenorphine Enrichment via Reversed Phase Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current processes for synthesizing buprenorphine result in low yields and high levels of impurities, particularly chemically similar side products like Impurity A, which are difficult to separate using existing techniques, failing to meet purity standards set by ICH and USP.
Innovation Solution
A method using preparative reversed phase chromatography to enrich buprenorphine by forming a feed solution with a solvent mixture, contacting it with a stationary phase, and introducing a mobile phase to elute a product fraction containing 80-100% of the buprenorphine, while removing impurities like Impurity A through selective adsorption and desorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional liquid phase separation and crystallization techniques are used to separate buprenorphine from impurities, then the process is simple to operate, but the separation effectiveness is poor due to similar chemical structures
Solution Approach 1:
The patent applies parameter changes by modifying the chemical environment parameters (pH, solvent composition, ionic strength) to alter the separation characteristics between buprenorphine and impurities. Different mobile phases (acidic, neutral, basic conditions) are used to optimize the resolution of chemically similar compounds that cannot be separated by traditional methods.
Solution Approach 2:
The patent uses stationary phases as intermediaries that provide selective interaction with buprenorphine and impurities. The stationary phase acts as a mediator that temporarily retains compounds based on their chemical properties, enabling separation that would be impossible through simple liquid-liquid extraction or crystallization.
2Productivity
If existing synthesis processes are used to produce buprenorphine, then the production cost is lower, but the yield is low and impurity levels are high
Solution Approach 1:
The patent extracts and removes specific impurities (Impurity A and Impurity D) from the buprenorphine product through targeted chromatographic separation. This selective extraction allows recovery of high-purity buprenorphine while eliminating side products that are difficult to avoid in synthesis.
Solution Approach 2:
The patent employs parameter changes in the form of gradient elution and pH adjustment to optimize both yield and purity. By controlling mobile phase composition and flow conditions, the process maximizes buprenorphine recovery while ensuring impurity removal meets pharmaceutical standards.
3Manufacturing precision
If chromatographic techniques are used to separate chemically similar impurities, then the purity of buprenorphine is improved, but the process complexity and cost increase
Solution Approach 1:
The patent segments the separation process into distinct chromatographic stages using different stationary and mobile phase combinations. This segmentation allows each impurity to be addressed with optimized conditions, achieving high purity while maintaining process manageability through systematic separation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively increases the purity of buprenorphine to meet current pharmaceutical standards by selectively separating buprenorphine from chemically similar impurities, improving yield and ensuring compliance with ICH and USP guidelines.
Implementation Method 1
contacting the first feed solution with a stationary phase and introducing a first mobile phase into the stationary phase
Implementation Method 2
eluting a first product fraction from the stationary phase. The first product fraction includes between about 80% and 100% of the amount of buprenorphine contained in the crude buprenorphine composition
Data Source
AI summary
The present invention provides processes for the enrichment of buprenorphine in a product. In particular, the present invention provides processes for the enrichment of buprenorphine in a product using chromatographic techniques.